Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

31.43
Delayed Data
As of Jun 24
 -2.07 / -6.18%
Today’s Change
16.64
Today|||52-Week Range
51.99
-11.84%
Year-to-Date
Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More
Jun 22 / TheStreet.com - Paid Partner Content
Is Acadia Pharmaceuticals' Stock Still a Buy?
Jun 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close33.50
Today’s open30.88
Day’s range30.09 - 32.90
Volume9,672,341
Average volume (3 months)3,165,391
Market cap$3.6B
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)-71.58%
Earnings growth (this year)-9.20%
Earnings growth (next 5 years)+18.27%
Revenue growth (last year)-49.17%
P/E ratioNM
Price/Sales58,810.80
Price/Book16.04

Competitors

 Today’s
change
Today’s
% change
ICPTIntercept Pharmaceut...-11.34-7.35%
NBIXNeurocrine Bioscienc...-1.31-2.94%
ENDPEndo International P...-0.99-6.25%
AKRXAkorn Inc-1.33-4.57%
Data as of 4:00pm ET, 06/24/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)-$0.48
Annual revenue (last year)$61.0K
Annual profit (last year)-$164.4M
Net profit margin-269,578.69%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stephen R. Davis
Vice President-Technology Development &
Operations
James A. Nash
Corporate headquarters
San Diego, California

Forecasts

Partner Offers

Search for Jobs